Objectives. Our goals were to determine the incidence of HZ and PHN in a primary care population and to identify risk indicators for the occurrence of PHN.
Introduction
Herpes zoster (HZ) or shingles is a common disease, with a reported incidence varying from 2.2 to 3.4/1000 patients/year. [1] [2] [3] This incidence increases with age. 2, 4 HZ is caused by a localized infection with the varicella zoster virus and represents a recrudescence from a latent phase in which the virus is dormant in sensory ganglia after a primary infection (chicken pox). Reactivation of the virus and its spread to the corresponding dermatome result in HZ. The symptoms include a painful, vesicular rash with erythema. HZ is a self-limiting disease for most patients: healing of the skin and resolution of pain generally occur within 3-4 weeks. The most common complication of HZ is persistent pain, also called postherpetic neuralgia (PHN), which may last for several months to years.
Although associated with HZ, PHN is considered a distinct disorder with its own pathogenesis. [4] [5] [6] Some controversy exists, however, about the exact definition of PHN. Most authors define PHN as pain persisting beyond a specified interval (1 4,7 or 3 8 months) after the outbreak of the rash. Others define it as pain persisting beyond a specified interval after rash healing. 9 There is also disagreement with regard to the classification of PHN. For example, Dworkin and Portenoy have proposed a classification of HZ pain into an acute phase (first month after the onset of the rash), a subacute phase (1-4 months after the onset) and a chronic phase (Ͼ4 months), 10 while Johnson has made a distinction between early PHN (1-6 months after the onset) and late PHN (Ͼ6 months). 11 PHN occurs in 9-19% of all HZ patients. Its incidence is age dependent: the risk of PHN is low (2%) in patients younger than 50 years of age, ~20% in those older than 50 years and ~35% in those over the age of 80 years. 3, 12, 13 Pain from PHN has a potentially high impact on the quality of life. To date, a number of treatment strategies, including amytriptyline, 8, 14 gabapentin, 15 oxycodone 16 and a lidocaine patch, 17 have demonstrated some degree of efficacy. However, because many patients still suffer from pain despite such treatment, the value of several preventive strategies has been investigated. 18 The efficacy of antiviral medication in preventing PHN, for example, is controversial. In fact, meta-analyses have shown no or only a partial effect on the incidence of PHN, although the duration of the pain might be reduced. 19, 20 In contrast, a small randomized control trial showed that early medical treatment with amitriptyline causes a reduction in the occurrence of PHN. 21 Two retrospective studies have also shown a reduction in the occurrence of PHN when an epidural injection of corticosteroids and local anaesthetics were given in the acute phase of HZ. 22, 23 Dworkin and Portenoy 6 mentioned the following risk factors for PHN in their review on HZ: older age, severity of the HZ infection, sensory dysfunction in the affected dermatome, a painful prodrome and fever у38°C in the acute phase. Others have reported ophthalmic localization, 3, 12, 24, 25 psychosocial problems, 26, 27 immunoincompetence, connective tissue disease 28 and diabetes 29 as risk indicators.
Although nearly all HZ and PHN patients are diagnosed and treated by a GP, few studies have looked into the incidence and risk indicators in a primary care setting. 3, 12, 13, 25 For this reason, we determined retrospectively the incidence of HZ and PHN in patients registered in a general practice research database and analysed the risk indicators for PHN.
Methods
Patients and setting Data were collected from the General Practice Research Database (HNU: Huisartsen Netwerk Utrecht 30 ). This research network is a co-operation between the Julius Center for General Practice and Patient Oriented Research and 22 general practices in six different locations. The participating GPs use a computerized medical record system to register all patient contacts. The general purpose of this registration is to support the GP during basic daily practice activities and to supply data for scientific research. The total patient population of the HNU consists of ~49 000 people and can be considered as a dynamic population cohort with rather stable size. Its age and sex ratios are comparable with those of the Dutch population. 31 All HZ patients diagnosed between 1 August 1994 and 31 July 1999 were identified by searching the database for the ICPC code32 S70 (HZ) and for free text ('zoster'). After the search, one of the authors (JWM) visited the general practices and reviewed the full-text medical records of the selected patients. When the diagnosis HZ was only mentioned in the differential diagnosis or in the free text (e.g. "does not look like zoster", "prodrome zoster?", "patient fears zoster"), but not confirmed afterwards, patients were excluded from the analysis.
Registration
The presented duration of pain was recorded for each HZ patient. PHN was defined in this study as any pain that persisted at least 1 month after HZ diagnosis. Those patients who still had pain 3 months after HZ diagnosis were also registered. The total duration of pain was measured as the length of time between the first and last patient contact during which pain was reported or an analgesic was prescribed. The longest follow-up was 5 years. Additional information was registered with regard to possible risk factors for PHN, including age, gender, localization, co-morbidity, medication and painful prodrome. Relevant co-morbidity included diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and having a psychological problem at the time of HZ diagnosis. Relevant pharmacotherapy comprised corticosteroids (at the time of or within 14 days before diagnosis) and psychopharmaceuticals (anxiolytics and/or antidepressants at the time of or within the 3-month period before diagnosis). We also registered the frequency of consultations the year before diagnosis and the chronic use of analgesics (three or more prescriptions in the year before diagnosis) since these two factors could affect our outcome parameters.
Data analysis
Data were analysed using SPSS for Windows, version 9.0 (SPSS Inc, Chicago, IL). Analyses were performed to determine if clustering (on a practice level) was an influential factor. Incidence and prevalence rates were standardized to the European standard population. We first assessed univariate associations of the potential risk indicators with PHN. Then, we used gender and all of the determinants that had a P-value Ͻ0.1 in the univariate model to build a multivariate logistic regression model. This latter model was used to assess the independent influence of potential risk factors on the occurrence of PHN. The same determinants were also used in a multivariate logistic regression analysis of PHN patients who still had pain 3 months after HZ diagnosis. The potential correlation between consultation frequency and PHN was checked using Spearman's correlation coefficient.
Family Practice-an international journal Results A search of the database resulted in 1234 possible patients, 837 of whom were diagnosed as having HZ, equally distributed over the 5-year period. Of the 397 patients who did not actually have HZ, GPs initially thought the symptoms pointed to a possible or a beginning HZ and registered it as such. These patients were excluded from the analysis. The calculated incidence of HZ was 3.4/1000 patients/year [95% confidence interval (CI) 2.9-3.9]. Extrapolated to the standard European population, 33 the incidence was 3.6/1000 patients/year (95% CI 3.1-4.1). A total of 47% of all HZ patients were at least 55 years old (Table 1 ). In addition, the risk of PHN increased with age. Persistent pain 1 month after HZ diagnosis was reported in the medical records of 6.5% (95% CI 4.9-8.3) of the HZ patients and in 2.6% (95% CI 1.7-4.0) 3 months after HZ diagnosis (extrapolated to the standard European population 33 risk of pain at 1 month: 6.9%, 95% CI 5.3-8.8; risk of pain at 3 months: 2.9%, 95% CI 1.9-4.2). These percentages increased with age (Table 2) . Adjustment for clustering did not essentially influence these rates.
In the univariate analysis, age, ophthalmic localization, DM, use of psychopharmaceuticals and painful prodrome appeared to be possible risk indicators for the occurrence of PHN (P-value Ͻ 0.10). After multivariate analysis, however, only age [55-74 years, adjusted odds ratio (OR) 4.2, 95% CI 1.8-9.7; Ͼ75 years, OR 10.7, 95% CI 4.6-25.1] and ophthalmic localization (OR 2.1, 95% CI 1.0-4.6) independently contributed to the risk of developing PHN (Table 3 ). Persistent pain 3 months after HZ diagnosis was only independently associated with age. Ophthalmic localization showed an adjusted OR of 2.3. This odds ratio, however, was not significant (Table 4) .
No correlation was found between consultation frequency or analgesic use and PHN (data not shown).
Discussion
The HZ incidence found in this study is similar to that reported in other studies, 1-3 while the 6.5% risk of developing PHN is somewhat lower. 3, 12, 13 Of the potential risk indicators studied, we found that only age and ophthalmic localization contributed independently to the incidence of PHN.
Some aspects of this study, however, must be addressed in order to appreciate the results. First, the study was retrospective and therefore potentially prone to registration inadequacy, especially to under-reporting. In addition, our analysis was based on the registration of complaints that were presented actively by patients. We believe that consulting a GP is a reliable indicator that people have significant pain. Those with mild pain, however, might have bought analgesics without consulting their GP. The cumulative incidence of PHN in our study, therefore, probably includes only those patients with more severe pain. This would also explain why the incidence in our study is lower than that in other studies. Nevertheless, we would like to emphasize that our incidence figure is likely to reflect the clinically relevant dimension of PHN in primary care. Secondly, migration and death might also lead to underestimation of the incidences of HZ and PHN. This factor probably did not play an important role in our study since our HZ cases were equally distributed over the 5-year period and the incidence is comparable with that reported in other studies. [1] [2] [3] Thirdly, we lacked reliable information regarding the severity of pain and rash. Therefore, we were unable to analyse the influence of these potential risk indicators. Finally, the number of participating general practices was quite small, which could affect the generalizability of the study results. The practices do, however, include ~49 000 patients, and patient characteristics are comparable with those of the Dutch primary care population. This is confirmed by the HZ incidence (3.4/1000 patients/year), which corresponds to the HZ incidence in The Netherlands (2.8/1000 patients/year). 34 Our results support a number of earlier studies 3, 4, 12, 13, 28 that reported age as a risk indicator of PHN, i.e. the older the patient, the higher the risk. In addition, our finding that no children or adolescents developed PHN confirms the results of a study conducted in Iceland on HZ in children and adolescents. 35 This higher risk of developing PHN with increasing age has often been explained by the decreasing immunity seen in older people. Like others, 4,5 however, we did not observe that immunity-depressing factors such as DM, RA, SLE or the use of corticosteroids increased the risk of PHN. Nor could we detect any risk of reported psychological stress at the time of HZ on the development of PHN, a fact that has been noted by others. 26, 27 Our finding of an ophthalmic localization of HZ as a risk indicator does support the results of earlier studies. 3, 12, 24, 25 Moreover, we found that a painful prodrome, which could be considered a sign of more severe HZ, was associated with an increased risk of PHN. The odds ratios, however, were not significant, probably due to the small number of patients. Moreover, the data on this risk indicator should be viewed with caution as the registration of this factor by the GPs might have been incomplete. We conclude that, so far, age and ophthalmic localization are the only factors that can help GPs identify patients at risk of developing PHN.
